• Veratridine in Cardiac and Sodium Channel Assays

  2026-09-25

  Veratridine provides a direct way to challenge voltage-gated sodium channel activity, while chamber-specific stem-cell cardiomyocytes offer a more informative cardiac context for interpreting responses. This workflow distinguishes established product data from proposed cardiac assay conditions and highlights controls that help separate channel effects from toxicity or differentiation variability.

• Phillygenin in Diabetic Nephropathy: Mechanisms

  2026-09-25

  A study in Phytomedicine reports that phillygenin reduced inflammation and apoptosis in high-glucose-exposed mouse podocytes and improved kidney injury measures in diabetic mice. Its value lies in connecting these effects with changes in TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling, while leaving important questions about direct targets and clinical relevance for future work.

• Neuromedin S (rat): Handling and Assay Workflow

  2026-09-24

  Neuromedin S (rat), SKU B5466, provides a defined peptide input for controlled studies of neuromedin U receptor and GPCR/G protein signaling. Use it in research assays with locally validated concentrations and controls; product details do not establish potency or suitability for diagnostic, therapeutic, or clinical use.

• Panoramic Hyperspectral Mapping of Cardiac Infarcts

  2026-09-24

  Kowalik and colleagues combined panoramic hyperspectral imaging with optical mapping to locate epicardial tissue classes and membrane-potential activity in the same infarcted hearts. The approach associated collagen-sensitive tissue classification with action-potential duration and arrhythmic events, offering a spatial framework for interpreting cardiac electrophysiology alongside tissue structure.

• Veratridine and the Identity Test in Cardiac Models

  2026-09-23

  Veratridine is a voltage-gated sodium channel opener that can serve as a functional challenge in chamber-specific cardiomyocyte research. This article explains how to interpret such challenges alongside human stem-cell differentiation findings—and where the evidence stops.

• SERCA2–CaN–FoxO1–FABP4 in Atherosclerosis

  2026-09-23

  The 2025 British Journal of Pharmacology study identifies the calcineurin/FoxO1/FABP4 axis as a mechanistic link between SERCA2 dysfunction, abnormal fatty acid handling, macrophage foam-cell formation, and atherosclerosis. Its combination of a SERCA2 C674S knock-in model, macrophage lipid assays, metabolomics, and pathway-directed interventions provides a rationale for evaluating FABP4 inhibition in disease settings driven by endoplasmic reticulum and calcium-signaling stress.

• Tamoxifen: Precision Tool, Hidden Variables

  2026-09-22

  Tamoxifen is both a selective estrogen receptor modulator and a powerful temporal switch for conditional genetics. This thought-leadership article connects its molecular activity to experimental design, highlights developmental confounding reported after prenatal exposure, and provides translational guidance for breast cancer research, prostate models, and CreER-mediated gene knockout studies.

• PINK1 Loss, Mitochondrial Iron, and Colon Tumors

  2026-09-22

  The reference study identifies mitochondrial iron accumulation as a druggable consequence of PINK1 deficiency in colorectal cancer. By combining transcriptomics, compartment-resolved iron measurements, pharmacological intervention, and MCU manipulation, it links impaired mitophagy to tumor growth and proposes iron reduction as a strategy for tumors with low PINK1 expression.

• Gastrodin, AT1 Signaling, and Reactive Astrocytes

  2026-09-21

  A 2024 European Journal of Neuroscience study shows that activated microglia can reshape astrocyte renin–angiotensin system and SIRT3 signaling through conditioned-medium communication. Its findings position AT1 signaling as a mechanistic link between astrocyte reactivity, inflammatory mediators, and neurotrophic responses, while also defining important limits for interpreting this in vitro model.

• o-Agatoxin IVA and Excitotoxicity in Cortical Cultures

  2026-09-21

  The 1996 study tested whether blocking P- and Q-type voltage-gated calcium channels with o-Agatoxin IVA could protect cultured cortical neurons from veratridine-, ouabain-, or NMDA-induced injury. Its central finding was negative but important: suppressing depolarization-evoked glutamate release did not necessarily prevent excitotoxic neuronal damage.

• CAR T Cells and mRNA Vaccines in CLDN6+ Tumors

  2026-09-20

  The reference Nature Medicine article highlights a first-in-human strategy pairing CLDN6-directed CAR T cells with repeated doses of a CLDN6-encoding mRNA vaccine, or CARVac. Its early clinical signals suggest that antigen delivery may improve CAR T-cell expansion and persistence, while the study design also illustrates the safety, biomarker, and interpretation challenges of translating mRNA-enabled immunotherapy to solid tumors.

• AO/PI Staining Solution for DN Cell Assays

  2026-09-19

  Discover how AO/PI Staining Solution strengthens diabetic nephropathy cell studies by separating membrane integrity from inflammatory and apoptotic mechanisms. This guide translates phillygenin pathway evidence into a more rigorous fluorescence-based cell-counting strategy.

• AZD6482: Designing Better PI3Kβ Assays

  2026-09-18

  AZD6482 is a highly selective PI3Kβ inhibitor with applications spanning kinase, platelet, and metabolic research. This guide explains how to use its selectivity while avoiding misinterpretation when designing assays inspired by RNA-foci studies in myotonic dystrophy.

• Phillygenin Signaling in Diabetic Nephropathy

  2026-09-18

  The reference study shows that phillygenin reduces hyperglycemia-associated inflammation and apoptosis in podocytes and improves renal injury in db/db mice. Its main contribution is the integration of TLR4/MyD88/NF-κB suppression with restoration of PI3K/AKT/GSK3β signaling, while its preclinical design leaves questions about direct pathway causality and clinical translation.

• DDRGK1 UFMylation and STAT3 in Osteoarthritis

  2026-09-17

  The reference study identifies DDRGK1-dependent UFMylation as a regulatory brake on STAT3 phosphorylation and nuclear translocation during osteoarthritis progression. By integrating human cartilage analysis, cartilage-specific mouse genetics, multi-omics, biochemical interaction assays, and pharmacological rescue, it provides a mechanistic framework for linking loss of DDRGK1 to inflammatory cartilage degeneration.

8016 records 1/535 page Next 12345 下5页 Last page